Zydus Lifesciences Ltd has dissolved Ampliman 2, France, a step‑down wholly owned subsidiary, effective January 9, 2026, company filings show. The dissolution was carried out without liquidation and forms part of an internal restructuring rather than an exit from the market.
Ampliman 2 was originally a wholly owned subsidiary of Zydus MedTech (France) S.A.S, which itself is a step‑down wholly owned subsidiary of Zydus Lifesciences. Following the dissolution, all assets and liabilities of Ampliman 2 were transferred to Zydus MedTech (France) S.A.S in accordance with regulatory provisions.
The regulatory disclosure was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Zydus Lifesciences indicated that the move will not affect its business operations, suggesting that the company’s activities and market presence will continue unchanged.
Industry filings confirm that the dissolution was executed without formal liquidation procedures, and the subsidiary’s legal and financial responsibilities have been consolidated into Zydus MedTech (France) S.A.S, streamlining the company’s European organisational structure.
